Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.

Mark C Markowski Eugene ShenderovMario A EisenbergerSushant KachhapDrew M PardollSamuel R Denmeade Emmanuel S Antonarakis

Published in: The Prostate (2020)

These cases of mCRPC suggest that immune checkpoint blockade may have therapeutic potential in patients with prostate cancer, especially following immune activation ("priming") using BAT and enzalutamide.

Keyphrases

prostate cancer
radical prostatectomy
bipolar disorder
mesenchymal stem cells
cell therapy
smoking cessation